个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
于鑫淼,中国医科大学附属第一医院乳腺外科教授、主任医师,硕士研究生导师。美国加州大学旧金山分校(UCSF)博士后。毕业于中国医科大学临床医学七年制英文班,曾荣获中国医科大学优秀博士毕业生,入选中国医科大学青年英才计划,并获得辽宁省科技进步二等奖。主要研究方向为乳腺癌信号通路及肿瘤微环境。主持包括国家自然科学基金和国家重点研发计划子课题在内的国家及省部级课题6项,以第一/通讯作者发表SCI论文10余篇。担任中华医学会肿瘤学分会乳腺肿瘤学组青年学者副召集人、辽宁省医学会肿瘤学分会青委会委员、沈阳市医师协会乳腺肿瘤专委会副主任委员、沈阳市抗癌协会乳腺癌专业委员常委、JCO中文版乳腺肿瘤专刊青年编委、中国人体健康促进会乳房再造专委会常委、中国妇幼保健协会医疗美容专业委员会肿瘤整形学组委员兼秘书、辽宁省细胞生物学学会乳腺肿瘤精准治疗与临床科研委员会委员兼秘书等。
1、辽宁省应用基础研究计划(青年专项),基质硬度通过HDAC7/PKM2/HIF1a介导的糖酵解调控乳腺癌侵袭和转移的机制研究,30万,在研
2、吴阶平医学基金会临床科研专项自助基金,早期乳腺癌淋巴结切除数量与预后关系的多中心回顾性研究,10万,在研
3、吴阶平医学基金会临床科研专项自助基金,辅助或新辅助曲妥珠单抗经治的HER2阳性乳腺癌晚期一线治疗选择的真实世界研究,5万,结题
4、国家自然科学基金(青年项目),ZNF326通过DBC1促进乳腺癌恶性表型的机制,23万,结题
5、辽宁省博士启动基金,细胞浆中的TMTM88及核转位后对乳腺恶性表型影响的机制研究,5万,结题
6、国家重点研发计划,促进基层国产创新医疗器械利用的政策创新解决方案,20万,结题
上传附件
支持扩展名:.rar .zip .doc .docx .pdf .jpg .png .jpeg上传附件
支持扩展名:.rar .zip .doc .docx .pdf .jpg .png .jpeg上传附件
支持扩展名:.rar .zip .doc .docx .pdf .jpg .png .jpeg2013/09-2016/07,中国医科大学,肿瘤学博士,导师:金锋
2009/07-2011/07,中国医科大学,外科学硕士,导师:金锋
2004/09-2009/07,中国医科大学,临床医学(七年制),学士
2024/12-至今,中国医科大学,附属第一医院,教授/主任医师
2019/12-2024/12,中国医科大学,附属第一医院,副教授/副主任医师
2018/9-2020/12, 美国加州大学旧金山分校(UCSF)博士后
2014/12-2019/12,中国医科大学,附属第一医院,讲师/主治医师
2011/07-2014/12,中国医科大学,附属第一医院,助教/住院医师
1、XV Wang, P Xu, M Cui, X Yu, L Wang, A literature survey of smart manufacturing systems for medical applications, Journal of Manufacturing Systems. 2024 Oct 76;502-519,
2、Gan X, Feng Y, Liu Y, Lin X, Yu X, Rong X, Han Q. Identification of zinc finger MIZ-type containing 2 as an oncoprotein enhancing NAD-dependent protein deacetylase sirtuin-1 deacetylase activity to regulate Wnt and Hippo pathways in non-small-cell lung cancer. Cell Mol Biol Lett. 2024 Sep 12;29(1):122.
3、Yu H, Li S, Li X, Liu Y, Wang Z, Cui M, Jin F, Yu X. Apolipoprotein L3 inhibits breast cancer proliferation and modulates cell cycle via the P53 pathway. J Cancer. 2024 Jul 2;15(14):4623-4635.
4、Li S, Jin Z, Song X, Ma J, Peng Z, Yu H, Song J, Zhang Y, Sun X, He M, Yu X, Jin F, Zheng A. The small nucleolar RNA SNORA51 enhances breast cancer stem cell-like properties via the RPL3/NPM1/c-MYC pathway.Mol Carcinog. 2024 Jun;63(6):1117-1132.
5、Yu H, Liu Y, Zhang W, Peng Z, Yu X, Jin F. A signature of cuproptosis-related lncRNAs predicts prognosis and provides basis for future anti-tumor drug development in breast cancer. Transl Cancer Res. 2023 Jun 30;12(6):1392-1410.
6、Li R, Zhang Q, Feng D, Jin F, Han S, Yu X. Case report: Lymph node metastases of breast cancer and thyroid cancer encountered in axilla. Front Oncol. 2022 Sep
7、Liu Y, Jin Z, Yu X, Zheng A, Jin F, Wang X. An insight into the invasion of breast ductal carcinoma in situ based on clinical, pathological and hematological data. PeerJ. 2022 Aug 31;10:e13966.
8、Liu Y, Fan Y, Jin Z, Cui M, Yu X, Jin F, Wang X. Axillary management for early invasive breast cancer patients: Who will truly benefit? Front Oncol. 2022 Aug 15;12:989975.
9、Wu SL, Yu X, Mao X, Jin F. Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis. BMC Cancer. 2022 Jul 18;22(1):782.
10、Liu Y, Wang X, Zheng A, Yu X, Jin Z, Jin F. Breast Lesions Diagnosed as Ductal Carcinoma In Situ by Ultrasound-Guided Core Needle Biopsy: Risk Predictors for Concomitant Invasive Carcinoma and Axillary Lymph Node Metastasis. Front Oncol. 2021 Sep 10;11:717198.
11、Li X, Cao Y, Yu X, Jin F, Li Y. A novel autophagy-related genes prognostic risk model and validation of autophagy-related oncogene VPS35 in breast cancer. Cancer Cell Int. 2021 May 17;21(1):265.
12、Drain AP, Zahir N, Northey JJ, Zhang H, Huang PJ, Maller O, Lakins JN, Yu X, Leight JL, Alston-Mills BP, Hwang ES, Chen YY, Park CC, Weaver VM. Matrix compliance permits NF-κB activation to drive therapy resistance in breast cancer. J Exp Med. 2021 May 3;218(5):e20191360.
13、Wu SL, Zhang X, Chang M, Huang C, Qian J, Li Q, Yuan F, Sun L, Yu X, Cui X, Jiang J, Cui M, Liu Y, Wu HW, Liang ZY, Wang X, Niu Y, Tong WM, Jin F. Genome-wide 5-Hydroxymethylcytosine Profiling Analysis Identifies MAP7D1 as A Novel Regulator of Lymph Node Metastasis in Breast Cancer. Genomics Proteomics Bioinformatics. 2021 Feb;19(1):64-79.
14、 Ma W, Zhao F, Yu X, Guan S, Suo H, Tao Z, Qiu Y, Wu Y, Cao Y, Jin F. Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature. J Transl Med. 2020 Nov 23;18(1):442.
15、Zheng A, Yu X, Fan L, Ma J, Jin F. Improving Education About Breast Cancer for Medical Students in China. J Cancer Educ. 2020 Oct;35(5):871-875.
16、 Li X, Li Y, Yu X, Jin F. Identification and validation of stemness-related lncRNA prognostic signature for breast cancer. J Transl Med. 2020 Aug31;18(1):331.
17、Wang M, Han Q, Su Z, Yu X. Transcription Factor ZNF326 Upregulates the Expression of ERCC1 and HDAC7 and its Clinicopathologic Significance in Glioma. Lab Med. 2020 Jul 8;51(4):377-384.
18、 Huang H, Yuan M, Wu SL, Ba J, Yu X, Mao X, Jin F. Clinical Significance of C-X-C Motif Chemokine Receptor 4 and Integrin αvβ6 Expression in Breast Cancer.J Breast Cancer. 2020 Apr;23(2):171-181.
19、Yu X, Wang M, Wu J, Han Q, Zhang X. ZNF326 promotes malignant phenotype of glioma by up-regulating HDAC7 expression and activating Wnt pathway. J Exp Clin Cancer Res. 2019 Jan 28;38(1):40.
20、Yu X, Wang M, Han Q, Zhang X, Mao X, Wang X, Li X, Ma W, Jin F. ZNF326 promotes a malignant phenotype of breast cancer by interacting with DBC1. Mol Carcinog. 2018 Dec;57(12):1803-1815.
21、Wang X, Li Y, Fan Y, Yu X, Mao X, Jin F. PTBP1 promotes the growth of breast cancer cells through the PTEN/Akt pathway and autophagy. J Cell Physiol. 2018 Nov;233(11):8930-8939.
22、 Mao X, Fan C, Yu X, Chen B, Jin F. DDEFL1 correlated with Rho GTPases activity in breast cancer. Oncotarget. 2017 Oct 26;8(68):112487-112497.
23、Mao X, Qiao Z, Fan C, Guo A, Yu X, Jin F. Expression pattern and methylation of estrogen receptor α in breast intraductal proliferative lesions. Oncol Rep. 2016 Oct;36(4):1868-74.
24、Zhang X, Yu X, Jiang G, Miao Y, Wang L, Zhang Y, Liu Y, Fan C, Lin X, Dong Q, Han Q, Zhao H, Han Y, Han X, Rong X, Ding S, Wang E, Wang E. Cytosolic TMEM88 promotes invasion and metastasis in lung cancer cells by binding DVLS. Cancer Res. 2015 Nov 1;75(21):4527-37.
25、Han Y, Zhang Q, Yu X, Han X, Wang H, Xu Y, Qiu X, Jin F. Immunohistochemical detection of STAT6, CD34, CD99 and BCL-2 for diagnosing solitary fibrous tumors/hemangiopericytomas. Int J Clin Exp Pathol.
26、Yu X, Zhang X, Zhang Y, Jiang G, Mao X, Jin F. Cytosolic TMEM88 promotes triple-negative breast cancer by interacting with Dvl. Oncotarget. 2015 Sep 22;6(28):25034-45.
27、Zhang X, Miao Y, Yu X, Zhang Y, Jiang G, Liu Y, Yu J, Han Q, Zhao H, Wang E. C6orf106 enhances NSCLC cell invasion by upregulating vimentin, and downregulating E-cadherin and P120ctn. Tumour Biol. 2015 Aug;36(8):5979-85.
28、Wang M, Yu X, Dong Q, Wang Y. Diversin is overexpressed in human gliomas and its depletion inhibits proliferation and invasion. Tumour Biol. 2014 Aug;35(8):7905-9.
29、Yu X, Wang M, Dong Q, Jin F. Diversin is overexpressed in breast cancer and accelerates cell proliferation and invasion. PLoS One. 2014 May 23;9(5):e98591.
30、Luan L, Zhao Y, Xu Z, Jiang G, Zhang X, Fan C, Liu D, Zhao H, Xu K, Wang M, Yu X, Wang E. Diversin increases the proliferation and invasion ability of non-small-cell lung cancer cells via JNK pathway. Cancer Lett. 2014 Mar 28;344(2):232-8.
31、于鑫淼,金锋.二代测序技术在乳腺癌精准治疗中的应用[J].中华乳腺病杂志(电子版),2018,12(04):238-241.
辽宁省科技进步奖二等奖
中国医科大学青年英才
中国医科大学 优秀博士毕业生
中国医科大学附属第一医院 优秀总住院
文件上传中...